Patents by Inventor Daishun Ling

Daishun Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9827313
    Abstract: The present invention relates to a nanoformulated self-assembled pharmaceutical composition for photodynamic therapy. More particularly, the present invention is directed to a self-assembled pharmaceutical composition for photodynamic therapy comprising a photosensitizer, a ligand A which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range and a method for manufacturing the same.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: November 28, 2017
    Assignees: SNU R&DB FOUNDATION, THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC, INSTITUTE FOR BASIC SCIENCE
    Inventors: Taeghwan Hyeon, Kun Na, Daishun Ling, Wooram Park, Sin-jung Park, Yang Lu, Kyoung Sub Kim, Michael J. Hackett, Byung Hyo Kim, Hyeona Yim, Yong Sun Jeon
  • Patent number: 9765187
    Abstract: The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cell comprising said ligand composition and MRI contrasting nanoparticles, and the methods for preparing them.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 19, 2017
    Assignees: SNR R&DB FOUNDATION, INSTITUTE FOR BASIC SCIENCE, THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC
    Inventors: Taeghwan Hyeon, Kun Na, Daishun Ling, Wooram Park, Byung Hyo Kim, Hyeona Yim, Kyoung Sub Kim, Michael J. Hackett, Sin-jung Park, Yang Lu, Yong Sun Jeon
  • Publication number: 20160089455
    Abstract: The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cell comprising said ligand composition and MRI contrasting nanoparticles, and the methods for preparing them.
    Type: Application
    Filed: March 27, 2015
    Publication date: March 31, 2016
    Inventors: Taeghwan Hyeon, Kun NA, Daishun LING, Wooram PARK
  • Publication number: 20160089436
    Abstract: The present invention relates to a nanoformulated self-assembled pharmaceutical composition for photodynamic therapy. More particularly, the present invention is directed to a self-assembled pharmaceutical composition for photodynamic therapy comprising a photosensitizer, a ligand A which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range and a method for manufacturing the same.
    Type: Application
    Filed: March 27, 2015
    Publication date: March 31, 2016
    Inventors: Taeghwan Hyeon, Kun Na, Daishun Ling, Wooram Park
  • Patent number: 9169355
    Abstract: Provided are a mussel adhesive protein-mimetic dispersion stabilizing agent to disperse nanoparticles in an aqueous medium, a colloidal solution including nanoparticles dispersed and stabilized by the dispersion stabilizing agent, and a contrast agent including the colloidal solution. More particularly, the mussel adhesive protein-mimetic dispersion stabilizer is a polyethyleneimine-graft-(poly-ethyleneglycol;polyDOPA) PEI-graft-(PEG;PDOPA). The graft polymer is formed of two parts. One is polyethyleneglycol grafted with a polyethyleneime which has an affinity to an aqueous medium, and the other is polyDOPA which has an affinity to the surface of nanoparticles. Because of those characteristics, the stabilizer shows a stable dispersion of nano particles in the aqueous medium.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: October 27, 2015
    Assignee: Hanwha Chemical Corporation
    Inventors: Taeghwan Hyeon, Kun Na, Daishun Ling, Wooram Park
  • Patent number: 8906346
    Abstract: Provided are a contrast agent for contrast imaging lymph node, which includes iron oxide nanoparticles dispersed and stabilized in an aqueous medium by a mussel adhesive protein-mimetic copolymer, a method for contrast enhanced lymphography using the foregoing contrast agent, and a method for diagnosis of lymph node cancers using the foregoing contrast agent. Using such a mussel adhesive protein-mimetic copolymer, the surface of iron oxide is modified and dispersed well in water to prepare a colloidal solution, which in turn forms the contrast agent containing the colloidal solution. The inventive contrast agent does not have toxicity and is easily taken up to the lymph node to exhibit excellent contrast imaging effects. The contrast agent of the present invention is useful for diagnosis of metastatic cancers.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: December 9, 2014
    Assignee: Hanwha Chemical Corporation
    Inventors: Ju Young Park, Wan Jae Myeong, Bong-Sik Jeon, Eung Gyu Kim, Eun Byul Kwon, Taeghwan Hyeon, Daishun Ling
  • Publication number: 20140023594
    Abstract: Provided are a contrast agent for contrast imaging lymph node, which includes iron oxide nanoparticles dispersed and stabilized in an aqueous medium by a mussel adhesive protein-mimetic copolymer, a method for contrast enhanced lymphography using the foregoing contrast agent, and a method for diagnosis of lymph node cancers using the foregoing contrast agent. Using such a mussel adhesive protein-mimetic copolymer, the surface of iron oxide is modified and dispersed well in water to prepare a colloidal solution, which in turn forms the contrast agent containing the colloidal solution. The inventive contrast agent does not have toxicity and is easily taken up to the lymph node to exhibit excellent contrast imaging effects. The contrast agent of the present invention is useful for diagnosis of metastatic cancers.
    Type: Application
    Filed: June 20, 2012
    Publication date: January 23, 2014
    Applicant: HANWHA CHEMICAL CORPORATION
    Inventors: Ju Young Park, Wan Jae Myeong, Bong-Sik Jeon, Eung Gyu Kim, Eun Byul Kwon, Taeghwan Hyeon, Daishun Ling
  • Publication number: 20130272965
    Abstract: Provided are a mussel adhesive protein-mimetic dispersion stabilizing agent to disperse nanoparticles in an aqueous medium, a colloidal solution including nanoparticles dispersed and stabilized by the dispersion stabilizing agent, and a contrast agent including the colloidal solution. More particularly, the mussel adhesive protein-mimetic dispersion stabilizer is a polyethyleneimine-graft-(poly-ethyleneglycol;polyDOPA) PEI-graft-(PEG;PDOPA). The graft polymer is formed of two parts. One is polyethyleneglycol grafted with a polyethyleneime which has an affinity to an aqueous medium, and the other is polyDOPA which has an affinity to the surface of nanoparticles. Because of those characteristics, the stabilizer shows a stable dispersion of nano particles in the aqueous medium.
    Type: Application
    Filed: December 28, 2011
    Publication date: October 17, 2013
    Applicant: HANWHA CHEMICAL CORPORATION
    Inventors: Taeghwan Hyeon, Kun Na, Daishun Ling, Wooram Park